Company intelligence / Profile preview

Ivra

Riverside, California, USA

Ownership: Private
Development stage: Other

Overview

Ivra is a biotechnology company dedicated to developing innovative treatments and preventatives for respiratory viral infections, with a primary focus on COVID-19. The company utilizes a proprietary decoy-based platform to create therapeutics that mimic human receptors, such as ACE2, to neutralize viruses before they can infect host cells. Their lead candidate is a nasal spray designed to provide a localized and effective barrier against SARS-CoV-2 and its variants. Founded on research from the University of California, Riverside, Ivra aims to provide accessible and broad-spectrum solutions for global health challenges.

Therapeutic areas: Infectious Diseases
Modalities: PeptidesRecombinant protein
Industry: Biotech

Partnerships

University of California, Riverside

Beyond the preview

Go deeper on Ivra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ivra.

Explore the full profile